Altimmune to Present at Upcoming H.C. Wainwright Investor Conferences October 12-13, 2021
GAITHERSBURG, Md., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc., (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the management team will be presenting virtually at the following H.C. Wainwright Investor Conferences:
- H.C. Wainwright 5th Annual NASH Investor Conference
Tuesday, October 12, 2021
3:30 pm Eastern Time
- H.C. Wainwright Hepatitis B Virus (HBV) Virtual Conference
Wednesday, October 13, 2021
4:30 pm Eastern Time
The sessions will be webcast and can be accessed by visiting the Events section of the Altimmune website.
Altimmune is a clinical stage biopharmaceutical company focused on developing treatments for obesity and liver diseases. Our pipeline includes next generation peptide therapeutics for obesity, NASH (pemvidutide), and chronic hepatitis B (HepTcell™). For more information, please visit www.altimmune.com.
Investor & Media Contacts:
Chief Financial Officer